Ciprofloxacin

Drug Profile

Ciprofloxacin

Alternative Names: Ciflox; CIPRO; Ciprobay; Ciprofloxacin hydrochloride; Ciproxan; Ciproxin; Ciproxine; Cunesin

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Class Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute sinusitis; Anthrax; Gonorrhoea; Intestinal infections; Intra-abdominal infections; Nosocomial pneumonia; Respiratory tract infections; Skin and soft tissue infections; Typhoid; Urinary tract infections

Most Recent Events

  • 26 Jul 2016 The US FDA approved label for ciprofloxacin carries a boxed warning
  • 15 Mar 2016 Biomarkers information updated
  • 02 Nov 2012 Bayer and Medsintez agree to manufacture and market anti-infective ciprofloxacin in Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top